Loading...
XNAS
AXDX
Market cap952kUSD
May 14, Last price  
0.03USD
Name

Accelerate Diagnostics Inc

Chart & Performance

D1W1MN
XNAS:AXDX chart
No data to show
P/E
P/S
0.08
EPS
Div Yield, %
Shrs. gr., 5y
33.72%
Rev. gr., 5y
4.70%
Revenues
12m
-2.99%
502,110212,701183,130475,5201,269,8862,245,6281,121,166236,00048,285122,000147,000246,0004,177,0005,670,0009,297,00011,165,00011,782,00012,752,00012,059,00011,698,000
Net income
-50m
L-18.78%
-2,090,800-3,030,621-1,924,243-1,680,342-714,197641,747-378,761-5,311,000-15,281,821-30,933,000-45,498,000-66,374,000-62,882,000-88,326,000-84,305,000-78,208,000-77,702,000-62,493,000-61,618,000-50,045,000
CFO
-24m
L-39.81%
-1,599,569-2,640,956-1,535,667-963,728-225,656-789,600448,481-816,000-9,748,951-18,785,000-35,126,000-53,408,000-55,746,000-67,756,000-64,794,000-50,394,000-47,323,000-48,728,000-40,196,000-24,194,000
Earnings
Aug 06, 2025

Profile

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
IPO date
Oct 27, 1993
Employees
179
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
11,698
-2.99%
12,059
-5.43%
12,752
8.23%
Cost of revenue
25,682
34,862
36,364
Unusual Expense (Income)
NOPBT
(13,984)
(22,803)
(23,612)
NOPBT Margin
Operating Taxes
(66)
850
(77)
Tax Rate
NOPAT
(13,918)
(23,653)
(23,535)
Net income
(50,045)
-18.78%
(61,618)
-1.40%
(62,493)
-19.57%
Dividends
Dividend yield
Proceeds from repurchase of equity
29,982
4,000
33,320
BB yield
Debt
Debt current
16,512
2,286
58,355
Long-term debt
50,064
39,326
23,454
Deferred revenue
1,122
Other long-term liabilities
6,556
1,164
1,537
Net debt
51,478
28,393
36,248
Cash flow
Cash from operating activities
(24,194)
(40,196)
(48,728)
CAPEX
(1,035)
(554)
Cash from investing activities
(509)
8,660
12,417
Cash from financing activities
27,053
9,019
31,630
FCF
(13,153)
(21,044)
(22,079)
Balance
Cash
15,098
13,219
45,561
Long term investments
Excess cash
14,513
12,616
44,923
Stockholders' equity
(6)
(669,455)
(607,538)
Invested Capital
13,873
691,073
664,351
ROIC
ROCE
EV
Common stock shares outstanding
23,302
12,477
8,216
Price
Market cap
EV
EBITDA
(10,563)
(19,549)
(20,612)
EV/EBITDA
Interest
13,117
7,743
3,771
Interest/NOPBT